Simulate 10,000 patients before protocol lock
QuantHealth simulates compound behavior across diverse virtual patients, helping clinical teams choose the dose, cohort, and design most likely to produce a readout.
Most protocol failures can be anticipated before they appear
Trial design depends on literature priors and expert judgment months before screening starts. When a weak assumption emerges, the cost is measured in years and substantial capital.
Three steps from compound data to a ranked protocol
Compound data in
You provide a mechanism summary, available PK parameters, prior study summaries, and indication. QuantHealth maps them to the relevant disease module and calibrates virtual patients to your compound class.
Simulation engine runs
Thousands of virtual patients, parameterized from published population pharmacology and real-world evidence, run through proposed dose scenarios. The Bayesian hierarchical model carries uncertainty through each parameter and reports credible intervals, not only point estimates.
Ranked design output
You receive a P(success) heatmap across dose and enrichment scenarios, responder subgroup stratification, and ranked protocol recommendations with an evidence trail for each. Outputs support regulatory discussion at pre-IND and end-of-Phase-2 meetings.
Where simulation makes a difference
Dose optimization
Find the dose that maximizes response in your target population while controlling adverse event probability, without relying on compound analogue assumptions.
Learn morePatient stratification
Find the subgroup driving efficacy before enrollment, focusing inclusion criteria without giving up generalizability.
Learn moreEndpoint and power analysis
Evaluate primary and secondary endpoint sensitivity across simulated population variance, identifying under-powered analyses before the trial protocol locks.
Learn moreTen thousand patient simulations revealed a subgroup response pattern we had missed in retrospective literature review. We revised the dosing arm, and the Phase II interim held up. That level of pre-trial clarity seemed impossible six months earlier.
Nadia Thornton, VP Translational Medicine, oncology biotech, QuantHealth early-access pilot program
Begin with one compound
One compound, one indication, one pilot engagement. Compare virtual results with your existing design assumptions before committing to a protocol. We will tell you upfront if your available data can support a useful simulation.